A Real World Database Study of Stroke Prevention in NVAF NVAF
Non-valvular atrial fibrillation (= NVAF). The term NVAF is restricted to cases in which atrial fibrillation occurs in the absence of rheumatic mitral stenosis or a prosthetic heart valve.
Patients

REVISIT-US: Real World Evidence of Stroke Prevention in Patients with Non-Valvular Atrial Fibrillation in the United States

Background

  • Little data exists regarding the effectiveness and safety of Xarelto® versus warfarin in non-valvular atrial fibrillation (NVAF NVAF
    Non-valvular atrial fibrillation (= NVAF). The term NVAF is restricted to cases in which atrial fibrillation occurs in the absence of rheumatic mitral stenosis or a prosthetic heart valve.
    ) patients treated outside of clinical trials1

Objective

  • Affirm the effectiveness and safety of previously OAC OAC
    Oral anticoagulant (= OAC). These are drugs that reduce the ability of the blood to clot.
    treatment naïve, newly initiated factor Xa factor Xa
    Pivotal component of blood clotting cascade. Stimulates the production of thrombin, the enzyme in the coagulation cascade that promotes the formation of blood clots.
    inhibition with Xarelto compared with warfarin in NVAF patients using data from a large, US administrative claims database1

Study Design

  • REVISIT-US was a retrospective administrative claims database study using US Truven MarketScan with data spanning from January 2012 to October 20141

End Point

  • Combination of ischaemic stroke or ICH ICH
    Intracranial haemorrhage (= ICH). This is bleeding within the skull.

Key Findings

  • Xarelto was associated with less ICH than warfarin
  • Xarelto may be associated with reductions in the combined end point

NVAF NVAF
Non-valvular atrial fibrillation (= NVAF). The term NVAF is restricted to cases in which atrial fibrillation occurs in the absence of rheumatic mitral stenosis or a prosthetic heart valve.
, non-valvular atrial fibrillation; OAC OAC
Oral anticoagulant (= OAC). These are drugs that reduce the ability of the blood to clot.
, oral anticoagulant anticoagulant
Anticoagulant drugs are used to treat and prevent blood clots. Sometimes referred to as ‘blood thinners’.
; ICH ICH
Intracranial haemorrhage (= ICH). This is bleeding within the skull.
, intracranial haemorrhage; NOAC, non-vitamin K agonist oral anticoagulant. Results are not intended for direct comparison between NOACs but between each NOAC and warfarin.